-8.1%
MOS vs GSK
+9.5%
-17.6%
-43.9%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 1y.
| Period | Portfolio | GSK | Excess | Alpha |
|---|---|---|---|---|
| 1D | -0.8% | -1.2% | +0.4% | -0.4% |
| 7D | +5.5% | -1.1% | +6.5% | +5.8% |
| 30D | +21.0% | +7.8% | +13.1% | +18.7% |
| 3M | -0.5% | +0.3% | -0.8% | -0.8% |
| 6M | +6.6% | +3.4% | +3.2% | +5.4% |
| YTD | -2.8% | +5.9% | -8.7% | -5.8% |
| 1Y | -8.1% | +8.2% | -16.3% | -10.5% |
| All | -8.1% | +9.5% | -17.6% | -10.5% |
Cumulative growth
Daily Returns
Daily percentage return beside GSK.
Daily Out/Under-Performance
Portfolio return minus GSK return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × GSK return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 1y: compounded portfolio wealth divided by compounded GSK wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
1y analysis · Full analysis span regression · 6 months rolling